Erratum to: Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia (J Hematol Oncol (2017) 10:39 DOI: 10.1186/s13045-017-0410-6);Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia

Journal of Hematology and Oncology

Volumn 10, Issue 1, 2017, Pages

  Kwok, Chau To ^a,b   Marshall, Amy D ^a,b   Rasko, John E J ^a,b,c   Wong, Justin J L ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Acute myeloid leukemia; Leukemia; m6A; RNA modification; TP53 mutation

Indexed keywords

ALKYLATED DNA REPAIR PROTEIN ALKB HOMOLOG 5; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; MESSENGER RNA; NUCLEOPHOSMIN; ADENOSINE; N(6)-RIBOSYLADENINE; TUMOR PROTEIN;

ACUTE MYELOID LEUKEMIA; ALKBH5 GENE; ARTICLE; CARCINOGENESIS; COPY NUMBER VARIATION; DNMT3A GENE; EPIGENETICS; EVENT FREE SURVIVAL; FLT3 GENE; FTO GENE; GENE; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE LOSS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIATION; HETEROZYGOTE; HUMAN; METTL14 GENE; METTL3 GENE; NPM1 GENE; OVERALL SURVIVAL; PATHOGENESIS; POINT MUTATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; YTHDF1 GENE; YTHDF2 GENE; ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MALE; METABOLISM; METHYLATION; MIDDLE AGED; MORTALITY; MUTATION; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADENOSINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, P53; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; METHYLATION; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; SEQUENCE DELETION; YOUNG ADULT;

EID: 85011281940     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-017-0419-x     Document Type: Erratum

References (10)

1. Liu N, Pan T. N6-methyladenosine-encoded epitranscriptomics. Nat Struct Mol Biol. 2016;23:98-102.
2. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M, Sorek R, Rechavi G. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201-6.
3. Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong G-M, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C, Chen J. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell. 2017;31:127-41.
4. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-4.
5. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med. 2013;368:2059-74.
6. Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program. 2013;2013:220-6.
7. Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014;15:e382-94.
8. Liu Y, He P, Liu F, Shi L, Zhu H, Zhao J, Wang Y, Chen X, Zhang M. Prognostic significance of NPM1 mutations in acute myeloid leukemia: a meta-analysis. Mol Clin Oncol. 2014;2:275-81.
9. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ. Genomic classification and prognosis in acute myeloid leukemia. New Engl J Med. 2016;374:2209-21.
10. Hou HA, Chou WC, Kuo YY, Liu CY, Lin LI, Tseng MH, Chiang YC, Liu MC, Liu CW, Tang JL, Yao M, Li CC, Huang SY, Ko BS, Hsu SC, Chen CY, Lin CT, Wu SJ, Tsay W, Chen YC, Tien HF. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J. 2015;5:e331.